MTNB
Matinas BiopharmaยทAMEX
--
--(--)
--
--(--)
MTNB Profile
Matinas Biopharma Holdings, Inc.
A clinical-stage biopharmaceutical company that develops various product candidates using lipid nano-crystal platform technology
1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921
--
Matinas Biopharma Holdings, Inc., a Delaware corporation, was incorporated in May 2013. The company is a clinical-stage biopharmaceutical company focused on delivering breakthrough therapies using lipid nanocrystals (LNC) platform delivery technology (LNC platform). The company is developing a range of products and developing product candidates, with an initial focus on severe fungal and bacterial infections. The company's proprietary cochlear implant delivery technology platform, licensed exclusively worldwide from Rutgers University, is specifically designed to directly target and safely deliver drugs to infected or inflamed sites. This innovative technology utilizes Cochleates nano-encapsulation of lipid crystal nanoparticles to encapsulate existing drugs, aiming to make them safer, more tolerable, less toxic and more bioavailable for oral use.
